Key facts
- It has raised $206.2M across 3 recorded rounds; the latest was Later Stage VC (Series B) ($110.0M) in Mar 2025.
- Notable investors include RA Capital Management, OrbiMed, Access to Advanced Health Institute, Adjuvant Capital, E&Investment — 12 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Curevo Vaccine
Funding rounds
3 roundsAbout Curevo Vaccine
Developer of a clinical-stage adjuvanted subunit vaccine intended to improve efficacy and broaden immune response. The company leverages its proprietary platform to design and develop vaccines that target various infectious diseases, enabling healthcare professionals to create more effective and long-lasting immunizations.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Bothell, WA, United States
- Founded
- 2017
- Employees
- 41
- Website
- curevovaccine.com/
- Ownership
- Privately Held (backing)
Curevo Vaccine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Curevo Vaccine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Curevo Vaccine in its N-PORT filings yet. We sweep new filings monthly.